Inogen Announces First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Stifel Raises Price Target After Inogen (INGN) Reports Better-Than-Expected 1Q
May 10, 2016 9:48 AM EDTStifel reiterated a Buy rating on Inogen, Inc (NASDAQ: INGN), and raised the price target to $52.00 (from $46.00), following the company's 1Q earnings report. INGN reported revenue of $43m, ahead of the consensus estimate of ~$41.7m. The strongest contributor to growth was the domestic business-to-business channel.... More
Inogen, Inc (INGN) Product Cycle Is More Important Than EBITDA Miss - Needham & Company
May 10, 2016 6:25 AM EDTNeedham & Company analyst, Mike Matson, thinks there is a buying opportunity after Inogen, Inc (NASDAQ: INGN) beat consensus revenue but missed consensus EBITDA in 1Q16. Management maintained 2016 guidance but the analyst upped his PT to $58 based on 5x 2017 sales.
Domestic business-to-business... More
Inogen (INGN) Reports Q1 EPS of 11c, Maintains Guidance
May 9, 2016 5:19 PM EDTInogen (NASDAQ: INGN) reported Q1 EPS of $0.11, may not compare to the analyst estimate of $0.12. Revenue for the quarter came in at $43 million versus the consensus estimate of $41.75 million.
Financial Outlook for 2016
The Company confirmed its 2016 revenue guidance of $187 to $191 million, which represents year-over-year growth of 17.6% to 20.1%. The Company continues to expect total revenue headwind from Medicare competitive bidding reimbursement reductions to be 3.5... More
